ISA Pharmaceuticals B.V.
http://www.isa-pharma.com/index.php
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From ISA Pharmaceuticals B.V.
Regeneron's 'Champion Of Cancer Vaccines' Forges New Path
Raquel Deering, one of In Vivo's 2020 Rising Leaders, discusses Regeneron's efforts to develop combination therapies, its collaborations with cancer vaccine companies, and its plans to become a major force in the oncology field.
Regeneron Increases Stake In ISA Pharma, Plans Pivotal Study
ISA Pharmaceuticals and Regeneron have updated their collaboration to outline a potential path to market for a combination of an anticancer immunotherapeutic and the checkpoint inhibitor, cemiplimab, for HPV-associated head-and-neck cancer.
Finance Watch: BIO Says Proposed Foreign Investment Regulations Will Lower Investment In US Biotech
Private Company Edition: BIO comments suggest definitions of personal data expand the scope of foreign investments in biotech companies that must be reviewed by the Committee on Foreign Investment in the United States (CFIUS). Also, NeuroRx’s $95m deal leads recent private financings.
Regeneron And Bluebird Team Up In Cell Therapy "Joint Venture"-Style Deal
Regeneron will make a $100m equity investment in bluebird to collaborate on the discovery of antibodies and T cell receptors, with the hope of building out in immuno-oncology and overcoming some of the early cell therapy challenges. Regeneron's business development chief talks to Scrip about its strategy.
Company Information
- Industry
- Biotechnology
-
Pharmaceuticals
- Drug Delivery
- Vaccines
-
Biotechnology
- Drug Discovery Tools